Locally advanced adenocarcinomas of the gastric cardia: results of pre-operative chemoradiotherapy - 27/06/08
Paul Balandraud [1],
Vincent Moutardier [1],
Marc Giovannini [2],
Marie-Hélène Giovannini [3],
Bernard Lelong [1],
Jérôme Guiramand [1],
Valérie Magnin [4],
Gilles Houvenaeghel [5],
Jean-Robert Delpero [1]
Voir les affiliationspages | 7 |
Iconographies | 10 |
Vidéos | 0 |
Autres | 0 |
Overall prognosis of adenocarcinomas of the gastro-esophageal junction remains poor as most patients present with advanced disease.
Aim |
To examine the effects of preoperative chemoradiotherapy in locally advanced adenocarcinomas of the gastro-esophageal junction.
Methods |
Forty-two consecutive patients received a course of radiotherapy (45 Gy, administred in 25 fractions) with concurrent infusion of 5-fluorouracil and cisplatin, followed by surgery. Endoscopic ultrasonography was used to assess response to chemoradiotherapy. A transhiatal or a transthoracic approach was used for surgical resection. Tumor size, node invasion and margins of resection were analyzed.
Results |
Thirty-eight patients underwent subsequent surgery and complete resection (R0) was achieved in 34. Operative mortality was 13.2% (5/38). A histological complete response was observed in 6 patients. Median survival was 23 months (range: 15-31) and median disease-free survival was 19 months (range: 15-23). At one and two years, 70.7 and 45.6% of the patients were alive, respectively. The pTNM status, node involvement and tumor size were predictors of survival.
Conclusions |
Pre-operative chemoradiotherapy is effective in patients with locally advanced carcinoma of the gastro-esophageal junction, resulting in high resection rates. However it seems to increase operative morbidity and mortality. Certain prognostic factors such as resection margins, need to be examined in further detail.
Plan
© 2004 Elsevier Masson SAS. Tous droits réservés.
Vol 28 - N° 8-9
P. 651-657 - août 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?